Wegovy Pill UK: Comparing Mounjaro, Wegovy and Other Weight Loss Medications
Medically reviewed by Alessandro Grenci, Superintendent Pharmacist (GPhC No. 2212970) Last updated: 22 June 2026
This article is intended for educational purposes and does not replace medical advice from a qualified healthcare professional. Prescription-only medicines are supplied only after an individual clinical assessment. Treatment suitability, effects and side effects vary between individuals.
Key Takeaways
- The Wegovy pill was approved by the MHRA on 11 June 2026, becoming the first GLP-1 tablet licensed for weight management in the UK.
- The tablet contains semaglutide, the same active ingredient as Wegovy injections.
- The Wegovy pill is approved but is not currently marketed in the UK.
- Mounjaro, Wegovy injections and Saxenda are available in the UK.
- Clinical studies report different average weight-loss outcomes for each treatment, but results cannot always be compared directly across separate trials.
- All GLP-1 weight-management treatments are prescription-only and require a clinical assessment.
The Wegovy pill was approved in the UK on 11 June 2026, becoming the first GLP-1 tablet licensed in the UK for weight loss and weight management. Several other GLP-1 weight-management treatments are already available in the UK, including Mounjaro, Wegovy injections and Saxenda.
Many people searching for the Wegovy pill may be trying to understand how the available weight-management medicines differ. The most appropriate option depends on factors such as clinical suitability, treatment preferences, tolerability and availability. This guide provides a general comparison.
Which Weight-Loss Medications Are Available in the UK?
As of June 2026, Mounjaro (tirzepatide), Wegovy (semaglutide injection) and Saxenda (liraglutide) are available in the UK by prescription. The Wegovy pill (oral semaglutide) has been approved by the MHRA but is not currently marketed in the UK. All are prescription-only medicines.
General Comparison of GLP-1 Weight-Loss Medications
| Treatment preference | Relevant option to discuss with a prescriber |
|---|---|
| A weekly injection | Mounjaro or Wegovy injection |
| A tablet that does not require injections | Wegovy pill |
| A longer-established GLP-1 option | Saxenda |
| A treatment currently available in the UK | Mounjaro, Wegovy injection or Saxenda |
The presence of a treatment in this table does not mean that it is suitable for a particular person. A prescriber must assess individual clinical circumstances.
GLP-1 Medications at a Glance
| Medication | General characteristics |
|---|---|
| Mounjaro | Weekly injection that acts on GIP and GLP-1 receptors |
| Wegovy | Established weekly semaglutide treatment |
| Wegovy pill | Daily semaglutide tablet for people who may prefer to avoid injections |
| Saxenda | Daily GLP-1 injection that may be considered when clinically appropriate |
Why Is the Wegovy Pill Notable?
GLP-1 weight-loss treatments have been available in the UK for several years, but previously licensed options required an injection.
The Wegovy pill is the first GLP-1 receptor agonist tablet approved specifically for weight loss and weight management in the UK.
This may provide another treatment format for eligible people who are unwilling or unable to self-inject. Needle anxiety can affect treatment preferences, and some people may find a daily tablet more familiar. However, the tablet has specific fasting and administration requirements that should also be considered.
How Have GLP-1 Weight-Loss Treatments Evolved?
| Year | Treatment | Type |
|---|---|---|
| 2017 | Saxenda (liraglutide) | Daily injection |
| 2023 | Wegovy (semaglutide 2.4 mg) | Weekly injection |
| 2023 | Mounjaro (tirzepatide) | Weekly injection |
| 2026 | Wegovy 7.2 mg | Weekly injection |
| 2026 | Wegovy pill (oral semaglutide) | Daily tablet |
Developments have included changes in dosing frequency, mechanisms of action and treatment formats.
What GLP-1 Weight-Loss Treatments Are Available in the UK?
| Treatment | Active ingredient | Injection or tablet | Weekly or daily | Current status |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | Injection | Weekly | Available |
| Wegovy | Semaglutide | Injection | Weekly | Available |
| Saxenda | Liraglutide | Injection | Daily | Available |
| Wegovy pill | Semaglutide | Tablet | Daily | Approved, but not currently marketed in the UK |
How Do Weight-Loss Outcomes Compare?
Clinical trials have reported different average weight-loss outcomes for these treatments:
- Mounjaro (tirzepatide): clinical trials have reported substantial average weight loss in eligible participants.
- Wegovy injection (semaglutide): the STEP trial programme has reported clinically significant average weight loss.
- Wegovy pill (oral semaglutide 25 mg): participants in the OASIS 4 trial experienced an average weight reduction of approximately 13.6% after 64 weeks, compared with approximately 2.4% in the placebo group.
- Saxenda (liraglutide 3 mg): clinical trials have demonstrated weight-loss benefits, although reported averages have generally been lower than those reported in trials of semaglutide and tirzepatide.
Results from separate clinical trials should not be treated as direct comparisons because study populations, designs and treatment durations may differ. Individual responses vary considerably, and trial averages do not predict individual outcomes. The most appropriate treatment depends on suitability, tolerability and clinical circumstances rather than reported efficacy data alone.
Mounjaro vs Wegovy vs Wegovy Pill
| Feature | Mounjaro | Wegovy | Wegovy pill |
|---|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide | Semaglutide |
| Administration | Weekly injection | Weekly injection | Daily tablet |
| Reported clinical trial outcomes | Substantial average weight loss | Substantial average weight loss | Substantial average weight loss |
| Needles required | Yes | Yes | No |
| Current UK status | Available | Available | Approved, but not currently marketed |
Mounjaro has been associated with substantial average weight loss in the SURMOUNT trial programme. Its action on both GLP-1 and GIP receptors distinguishes it mechanistically from semaglutide-based treatments.
Wegovy injection is an established treatment supported by the STEP trial programme. It is available in the UK and may be considered for eligible patients who are comfortable with weekly injections.
The Wegovy pill contains the same active ingredient as Wegovy injection, semaglutide, but is taken as a once-daily tablet. It may be considered where needle anxiety or injection practicality is a barrier to treatment.
In all cases, the most appropriate option depends on individual clinical circumstances, tolerability and personal preference rather than weight-loss outcomes alone.
What Is the Wegovy Pill?
The Wegovy pill is an oral tablet form of semaglutide developed by Novo Nordisk. It contains the same active ingredient as Wegovy injections but delivers it in tablet form rather than as a weekly self-injection.
Semaglutide is a GLP-1 receptor agonist, a class of medicines that mimics the action of a naturally occurring hormone called glucagon-like peptide-1. The body releases this hormone after eating. Semaglutide acts on areas involved in appetite regulation, which may help people feel fuller, reduce hunger and support weight reduction alongside appropriate diet and physical activity.
The tablet should be taken whole on an empty stomach after fasting for at least eight hours, with a sip of plain water. Patients should then wait at least 30 minutes before eating, drinking or taking other oral medicines. Taking it with food, too much water or without the required waiting period may reduce absorption. Patients should follow the instructions provided by their prescriber and in the patient information leaflet.
The MHRA approval was supported by the OASIS 4 phase 3 clinical trial. After 64 weeks of treatment alongside a reduced-calorie diet and increased physical activity, participants taking the tablet experienced an average weight reduction of approximately 13.6%, compared with approximately 2.4% in the placebo group. Results vary between individuals.
What Are the Side Effects of the Wegovy Pill?
The side-effect profile of the Wegovy pill is similar to that of other GLP-1 medicines. The most commonly reported effects are gastrointestinal and include nausea, diarrhoea, constipation and vomiting. These may occur during dose escalation. Patients should contact a doctor, pharmacist or nurse if side effects are persistent, concerning or severe.
Treatment begins at a low dose and is increased gradually in accordance with the licensed dosing schedule and the prescriber's instructions. Patients should not change their dose without clinical guidance.
Mounjaro (Tirzepatide)
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, a weekly injection manufactured by Eli Lilly. It was approved by the MHRA for weight management in the UK in 2023 and is available by prescription for eligible patients.
How Does It Work?
Mounjaro acts on two receptors: the GLP-1 receptor and the GIP receptor. GIP is another gut hormone involved in metabolic processes and appetite regulation.
The weekly injection is administered using a pre-filled injection pen. It is injected subcutaneously, usually into the abdomen, thigh or upper arm, in accordance with the product instructions and advice from a healthcare professional.
Characteristics
- Once-weekly dosing
- Acts on both GLP-1 and GIP receptors
- Clinical trials have reported substantial average weight loss
- Available in several dose strengths for gradual dose escalation under clinical supervision
Considerations
- Requires a weekly injection
- Gastrointestinal side effects are common, particularly during dose escalation
- NHS access is subject to relevant eligibility criteria and local pathways
- Suitability and dosing must be assessed by a qualified prescriber
Wegovy (Semaglutide Injection)
What Is Wegovy?
Wegovy is the brand name for semaglutide, a weekly injection manufactured by Novo Nordisk. It is approved for weight management in eligible patients in the UK. The established maintenance dose is 2.4 mg weekly. A maximum dose of up to 7.2 mg weekly was authorised in January 2026 for adults with obesity, and a single-dose 7.2 mg pen was approved in April 2026. The higher dose is not suitable for every patient and must only be used as prescribed.
How Does It Work?
Wegovy activates GLP-1 receptors involved in appetite regulation. This may help reduce hunger, increase feelings of fullness and support weight reduction alongside a reduced-calorie diet and increased physical activity.
It is administered as a weekly subcutaneous injection using a pre-filled pen.
The Wegovy pill and Wegovy injection contain the same active ingredient, semaglutide, although they have different formulations, dosing schedules and administration methods.
Characteristics
- Once-weekly dosing
- Evidence from the STEP clinical trial programme
- Available in the UK through private prescribing services and eligible NHS pathways
Considerations
- Requires a weekly injection
- Gastrointestinal side effects are common, particularly during dose escalation
- NHS access is subject to specific eligibility criteria and local pathways
- Dose changes should only be made under the direction of a prescriber
Saxenda (Liraglutide)
What Is Saxenda?
Saxenda is the brand name for liraglutide 3 mg, a daily injection manufactured by Novo Nordisk. It is an established GLP-1 treatment for weight management in the UK and has been available since 2017.
How Does It Work?
Like other GLP-1 medicines, Saxenda mimics the action of the GLP-1 hormone and may reduce appetite and promote feelings of fullness. Liraglutide has a shorter half-life than semaglutide, which is why it requires daily rather than weekly dosing.
Characteristics
- Longer-established use than some newer GLP-1 treatments
- Available in the UK, including through some NHS pathways
Considerations
- Requires a daily injection
- Clinical trials have generally reported lower average weight-loss outcomes than separate trials of semaglutide or tirzepatide
- Suitability depends on individual clinical circumstances
Saxenda may be prescribed in specific clinical situations, including where other medicines are not appropriate.
How Does the Wegovy Pill Compare With Existing Treatments?
| Feature | Wegovy pill | Wegovy injection | Mounjaro |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Administration | Daily tablet | Weekly injection | Weekly injection |
| Needles required | No | Yes | Yes |
| Dosing frequency | Once daily | Once weekly | Once weekly |
| Fasting required | Yes | No | No |
| Current UK status | Approved, but not currently marketed | Available | Available |
Potential Benefits of the Wegovy Pill
A daily tablet may be a suitable format for some eligible patients with needle anxiety or those who find injections difficult to self-administer.
Potential Limitations
Daily administration is more frequent than once-weekly injections. The fasting and administration requirements may also be inconvenient for some people. The Wegovy pill will not necessarily be suitable for everyone.
Should You Wait for the Wegovy Pill or Discuss Currently Available Treatment?
Factors that may be relevant include:
- Whether avoiding injections is a significant treatment preference
- Whether treatment is clinically indicated at present
- Whether a currently available medicine is suitable
- The practical requirements of taking a daily tablet while fasting
- The prescriber's assessment of the risks, benefits and available options
There is no single approach that is suitable for everyone. A qualified prescriber can discuss whether it is appropriate to wait for oral semaglutide or consider a currently available treatment. Patients should not start, stop, switch or alter prescription medication without clinical guidance.
Which Weight-Loss Medication Might Be Appropriate?
People Who Dislike Injections
The Wegovy pill is the first licensed GLP-1 weight-management treatment in the UK that does not require an injection. It may be considered once commercially available, subject to clinical assessment.
People Considering Currently Available Treatment
Mounjaro, Wegovy injections and Saxenda are currently available through registered UK prescribing services for eligible patients.
Differences in Mechanism
Mounjaro acts on both GIP and GLP-1 receptors. Semaglutide and liraglutide act on GLP-1 receptors. A newer or different mechanism does not necessarily mean that a medicine is more suitable for an individual patient.
The Importance of a Clinical Assessment
All GLP-1 weight-management medications are prescription-only. Access requires an assessment of factors including BMI, medical history, current medications, potential side effects and clinical suitability. Treatment decisions should be made with a qualified doctor, pharmacist or prescriber.
Can You Get the Wegovy Pill in the UK Yet?
Is the Wegovy Pill Approved by the MHRA?
Yes. The MHRA approved the Wegovy pill on 11 June 2026, making it the first GLP-1 tablet licensed for weight loss and weight management in the UK.
Is the Wegovy Pill Available in the UK?
Not currently. As of 22 June 2026, the Wegovy pill is authorised but is listed as not currently marketed in the UK.
How Much Will the Wegovy Pill Cost?
No confirmed UK retail price is available at the time of writing. Pricing may vary when the product is commercially launched.
When Will the Wegovy Pill Launch in the UK?
No confirmed UK commercial launch date has been announced at the time of writing.
Will It Be Available on the NHS?
The MHRA has confirmed that the tablet is not currently available through the NHS. Decisions about NHS use are subject to established processes, including evaluation by NICE. No timeframe should be assumed unless confirmed by the relevant authorities.
Can I Buy the Wegovy Pill Online?
Once commercially available, it should only be obtained from a registered UK pharmacy or prescribing service following an appropriate clinical assessment and with a valid prescription. Do not purchase prescription medicines from a source that does not require a prescription or appropriate assessment.
Frequently Asked Questions
Is the Wegovy Pill the Same as Wegovy Injections?
No. Both contain semaglutide, but they are different products with different formulations, dose schedules and administration methods. They are used for the same general indication but are not interchangeable without clinical guidance.
What Is the Difference Between Semaglutide and Tirzepatide?
Semaglutide and tirzepatide are medicines used for weight management in eligible patients, but they work differently. Semaglutide, the active ingredient in Wegovy injections and the Wegovy pill, acts on the GLP-1 receptor. Tirzepatide, the active ingredient in Mounjaro, acts on both the GLP-1 and GIP receptors.
Separate clinical trial programmes have reported different average weight-loss outcomes. These results should not be interpreted as a guaranteed outcome or a direct comparison unless the medicines were studied against each other under the same trial conditions.
Will the Wegovy Pill Replace Injections?
Not necessarily. The pill may suit some patients who prefer tablets or have needle anxiety. Weekly injections may remain more practical for other patients. Both treatment formats may continue to have a role, subject to individual clinical suitability.
Is the Wegovy Pill Better Than Mounjaro?
Neither medicine is universally better. They have different active ingredients, mechanisms and administration methods. Mounjaro acts on both GLP-1 and GIP receptors, while the Wegovy pill acts on GLP-1 receptors. The Wegovy pill produced an average weight reduction of approximately 13.6% after 64 weeks in the OASIS 4 trial, but this should not be treated as a direct comparison with results from separate Mounjaro trials. The most appropriate choice depends on individual circumstances.
What Is the Newest GLP-1 Medication in the UK?
As of June 2026, the Wegovy pill is the most recently approved GLP-1 weight-management treatment in the UK. It was approved by the MHRA on 11 June 2026.
Can I Switch From Injections to the Wegovy Pill?
The product information states that patients treated with semaglutide injection 2.4 mg once weekly can transition to semaglutide 25 mg tablets once daily, starting one week after their last injection. The effects of switching cannot be predicted precisely because absorption of oral semaglutide is more variable. Any switch must be assessed and directed by a qualified prescriber.
Which GLP-1 Medication Causes the Most Weight Loss?
Clinical trial programmes have reported different average outcomes, and individual responses vary considerably. Comparisons between separate trials may be unreliable because trial designs and participant populations differ. A medicine should not be selected solely on the basis of average weight-loss figures.
Are Weight-Loss Tablets Better Than Injections?
Neither format is objectively better for everyone. Tablets offer a needle-free option but require daily dosing and specific fasting conditions. Injections may require only once-weekly dosing and do not have the same fasting requirement. The appropriate option depends on lifestyle, preferences, tolerability and clinical suitability.
What Weight-Loss Medication Is Available in the UK Today?
Mounjaro, Wegovy injections and Saxenda are currently available by prescription. The Wegovy pill is MHRA-approved but is not currently marketed in the UK. All are prescription-only medicines.
What Is the Best Weight-Loss Medication in the UK?
There is no single best weight-loss medication for everyone. Each option has different characteristics, evidence, risks and administration requirements. The most suitable treatment depends on individual medical circumstances and should be discussed with a qualified prescriber.
How We Keep This Guide Updated
We regularly review MHRA announcements, NICE guidance, manufacturer updates, prescribing information and published clinical trial data to keep this guide accurate. Availability, pricing and prescribing guidance may change over time, and this article is updated when significant developments occur.
Medically Reviewed By
Alessandro Grenci Superintendent Pharmacist, medino GPhC Registration Number: 2212970
Sources
- MHRA. First GLP-1 tablet for weight loss approved in the UK. GOV.UK, 11 June 2026. https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk
- Novo Nordisk. Wegovy tablets Summary of Product Characteristics. Electronic Medicines Compendium, June 2026.
- Wadden TA et al. OASIS 4: oral semaglutide 25 mg for weight management. Phase 3 clinical trial data.
- NICE. Wegovy (semaglutide) for managing overweight and obesity. Technology appraisal TA875. National Institute for Health and Care Excellence.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216. SURMOUNT-1.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002. STEP 1.
- Novo Nordisk. Saxenda (liraglutide 3 mg) Summary of Product Characteristics. Electronic Medicines Compendium.
